It is fair to say that no other therapeutic agent has generated as much excitement in the kidney community in recent decades as SGLT2 inhibitors. Trial after trial has confirmed the substantive renoprotective and cardioprotective benefits on top of the standard of care including RAAS inhibitors. The initial studies however raised a few concerns, one…